FDA Approves Vidaza for Rare Pediatric Blood Cancer

The Food and Drug Administration (FDA) approved Vidaza (azacytidine) for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia, a rare blood cancer where certain types of white blood cells do not mature normally.

Read more: https://www.curetoday.com/view/fda-approves-vidaza-for-rare-pediatric-blood-cancer